Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Maria Rita Bongiorno, Maurizio Lombardo, Paolo Amerio, Maria Teresa Rossi, Andrea Chiricozzi, Serafinella Patrizia Cannavo’, Angelo Valerio Marzano, Francesca Prignano, Andrea Carugno, Claudio Feliciani, Marco Galluzzo, Andrea Conti, Luca Stingeni, Marina Talamonti, Concetta Potenza, Luca Bianchi, Stefano Piaserico, Aurora Parodi, Serafinella Patrizia Cannavo’, Giuseppe MicaliAndrea Conti, Concetta Potenza, Steven Paul Nisticò, Gabriella Fabbrocini, Pietro Quaglino, Francesco Loconsole, Maria Concetta Fargnoli, Iris Zalaudek, Sandra Giustini, Paola Savoia, Federico Bardazzi, Annamaria Offidani, Paolo Pigatto, Giuseppe Micali, Ketty Peris, Franco Rongioletti, Giuseppe Argenziano, Pietro Rubegni, Aurora Parodi, Paolo Gisondi, Giulia Rech

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen ‘cytokine storm’ of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.
Original languageEnglish
Pages (from-to)271-277
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume21
Publication statusPublished - 2021

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study'. Together they form a unique fingerprint.

Cite this